Fig. 5
The therapeutic effects of HUMSC-iHeps on acute liver failure trigged by CCl4-retrorsine. A Schematic diagram of HUMSC-iHeps transplantation into the livers of CCl4/retrorsine-treated nude mice. Female BALB/c nude mice (approximately 7 weeks old) were pretreated with 70 mg/kg retrorsine at 30th and 14th days before cell transplantation. B Body weight of CCl4/retrorsine-treated nude mice that received no transplanted cells, PHHs, and HUMSC-iHeps. C Kaplan-Meier survival curves of CCl4/retrorsine-treated nude mice that received just PBS, HUMSC-iHeps, and PHHs. *P < 0.05, log rank test. D Serum levels of ALP, ALT, and AST in moribund control mice (n = 3), surviving HUMSC-iHeps-transplanted mice (n = 3), and surviving PHHs-transplanted mice (n = 3). Human ALB levels were determined by ELISA in the sera of surviving HUMSC-iHeps-transplanted and PHHs-transplanted mice. E Co-expression of human ALB and human-mouse chimeric antibody AAT, TF, CK18, and CYP2E1 in retrorsine-treated livers from mice transplanted HUMSC-iHeps measured by immunostaining